Autres langues Erasca, Inc.

Actions

ERAS

US29479A1088

Marché Fermé - Nasdaq Autres places de cotation 22:00:00 01/05/2024			Varia. 5j.	Varia. 1 janv.
2,09 ^USD	+3,98%		+11,17%	-1,88%

02/04	ERASCA, INC. : Goldman Sachs toujours positif	ZM
27/03	Erasca, Inc. annonce ses résultats pour l'exercice clos le 31 décembre 2023	CI

Autres langues

Débloquez toutes les actualités sur toutes les entreprises : Ne manquez plus une opportunité d'investissement rentable !

Inscription 100% Gratuite

Erasca Announces Three Presentations at the 2024 ASCO Annual Meeting	24/04
North American Morning Briefing : Powell Awaited -2-	03/04
Erasca Announces $45 Million Oversubscribed Private Placement Financing	28/03
Erasca, Inc. Reports Earnings Results for the Full Year Ended December 31, 2023	27/03
Erasca Reports Fourth Quarter 2023 and Full Year 2023 Business Updates and Financial Results	27/03
Erasca, Inc. Reports Earnings Results for the Fourth Quarter Ended December 31, 2023	27/03
Erasca, Inc. announced that it expects to receive $45 million in funding	27/03
Erasca Enters Two Supply Deals With Novartis for Trametinib	14/02
Erasca Announces Two Clinical Trial Collaboration and Supply Agreements for Trametinib to Evaluate Naporafenib Combination in SEACRAFT-1 and SEACRAFT-2 Trials	14/02
Erasca, Inc. Announces Two Clinical Trial Collaboration and Supply Agreements for Trametinib to Evaluate Naporafenib Combination in SEACRAFT-1 and SEACRAFT-2 Trials	14/02
Erasca to Present at the Guggenheim Healthcare Talks 6th Annual Biotechnology Conference	01/02
Erasca to Present at the Guggenheim Healthcare Talks 6th Annual Biotechnology Conference	01/02
North American Morning Briefing : Boeing Drags -2-	08/01
Erasca to Present at the 42nd Annual J.P. Morgan Healthcare Conference	03/01
Erasca to Present at the 42nd Annual J.P. Morgan Healthcare Conference	03/01
Erasca, Inc. Receives FDA Fast Track Designation for Pan-RAF Inhibitor Naporafenib in Patients with Advanced NRAS-Mutated Melanoma	11/12
Erasca Granted FDA Fast Track Designation for Pan-RAF Inhibitor Naporafenib in Patients with Advanced NRAS-Mutated Melanoma	11/12
Erasca Granted FDA Fast Track Designation for Pan-RAF Inhibitor Naporafenib in Patients with Advanced NRAS-Mutated Melanoma	11/12
ErascaCEO Bought Shares Worth $1,696,179, According to a Recent SEC Filing	07/12
Erasca Completes Dose Escalation in Phase 1 Thunderbbolt-1 Trial; Extends Cash Runway to 2026	28/11

Aucun résultat pour cette recherche

Toute l'actualité Reco analystes Faits marquants Insiders Transcripts Communiqués Publications officielles Autres langues Idées de trading Articles Zonebourse Analyses Zonebourse

Autres langues Erasca, Inc.

Actions

ERAS

US29479A1088

Autres langues

Filtres